copd
major
global
concern
increasingli
context
age
popul
role
infect
diseas
pathogenesi
progress
known
import
yet
mechan
involv
remain
fulli
elucid
copd
pathogen
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
strongli
associ
acut
exacerb
copd
aecopd
clinic
relev
pathogen
stabl
copd
patient
remain
unclear
immun
respons
stabl
colon
copd
patient
compar
detect
aecopd
support
role
chronic
colon
copd
pathogenesi
perpetu
deleteri
immun
respons
advanc
molecular
diagnost
metagenom
allow
assess
microbecopd
interact
unpreced
person
precis
reveal
chang
microbiota
associ
copd
diseas
state
microbi
chang
associ
aecopd
diseas
sever
therapeut
intervent
becom
appar
renew
focu
place
microbiolog
copd
character
lung
microbiom
acut
chronic
state
character
bacteri
viral
fungal
microbiota
part
lung
microbiom
potenti
reveal
previous
unrecogn
prognost
marker
copd
predict
diseas
outcom
infect
suscept
address
knowledg
gap
ultim
lead
complet
understand
microbehost
interplay
copd
permit
clearer
distinct
acut
chronic
infect
granular
patient
stratif
enabl
better
manag
featur
copd
role
microb
infect
obstruct
lung
diseas
first
propos
british
hypothesi
state
recurr
infect
mucu
hypersecret
primari
caus
progress
airway
obstruct
smoker
howev
subsequ
studi
fail
detect
signific
associ
infect
lung
function
declin
consequ
exposur
noxiou
particl
gase
advanc
princip
caus
copd
wealth
evid
show
isol
bacteria
virus
fungi
airway
stabl
copd
patient
fact
signific
implic
diseas
pathogenesi
progress
treatment
place
renew
emphasi
microorgan
isol
copd
lung
drive
us
revisit
origin
british
hypothesi
advanc
diagnost
technolog
permit
accur
detect
specif
pathogen
copd
molecular
studi
shed
light
immun
respons
elicit
copdassoci
microorgan
metagenom
studi
reveal
microbi
consortia
healthi
diseas
individu
help
defin
pathogen
benefici
microb
associ
variou
diseas
state
major
implic
understand
copd
therapi
particularli
face
antibioticmedi
lung
dysbiosi
therapi
therefor
acut
chronic
infect
link
copd
progress
exist
compon
overarch
lung
microbiom
architectur
modul
therapeut
intervent
character
dynam
interact
microb
therapi
diseas
state
central
focu
copd
research
furthermor
emerg
antibiot
resist
copdassoci
pathogen
also
grow
intern
concern
greater
emphasi
antimicrobi
stewardship
ration
therapi
increas
import
ultim
role
microb
infect
copd
may
reveal
novel
prognost
marker
diseas
turn
provid
scope
focus
intervent
novel
therapeut
approach
period
worsen
respiratori
symptom
patient
copd
known
acut
exacerb
aecopd
mark
effect
lung
function
qualiti
life
health
socioeconom
burden
exact
natur
caus
event
often
difficult
establish
clinic
gener
infect
larg
blame
aecopd
link
either
bacteri
viral
pathogen
certain
subset
copd
patient
frequent
exacerb
concept
inher
suscept
acut
infect
copd
subsequ
trigger
aecopd
event
develop
sever
studi
demonstr
copd
patient
featur
impair
innat
immun
first
line
defenc
infect
alveolar
macrophag
resid
airway
provid
key
initi
respons
bacteria
recogn
remov
harm
pathogen
phagocytosi
copd
function
may
impair
recent
berenson
et
al
investig
tolllik
receptor
tlr
express
respons
alveolar
macrophag
collect
exacerbationpron
exacerbationfre
copd
patient
respons
exposur
common
copdrel
pathogen
includ
moraxella
catarrhali
streptococcu
pneumonia
haemophilu
influenza
alveolar
macrophag
exacerbationpron
patient
diminish
express
cytokin
respons
similarli
alveolar
macrophag
copd
patient
appear
phagocytos
h
influenza
pneumonia
poorli
compar
control
patient
yet
still
releas
reactiv
oxygen
speci
ro
togeth
studi
suggest
copd
patient
impair
respons
bacteri
colon
infect
turn
increas
suscept
aecopd
promot
oxid
stress
respons
fig
defect
innat
immun
may
also
play
role
increas
suscept
virus
recognit
viral
infect
innat
immun
system
essenti
coordin
effect
antivir
respons
airway
yet
patient
mice
copd
cascad
recognit
respons
falter
involv
increas
phosphatidylinositol
respons
impair
antivir
stress
granul
format
includ
type
interferon
ifn
signal
healthi
host
pathogen
recognit
trigger
ifn
pathway
hinder
viral
replic
mediat
adapt
immun
respons
epitheli
cell
constitut
type
ifn
critic
protect
cell
lung
fibroblast
expos
cigarett
smoke
respons
reduc
even
stimul
yield
diminish
antivir
respons
furthermor
mucociliari
clearanc
key
remov
viru
airway
appear
perturb
copd
cigarett
smoke
exposur
reduc
number
length
cilia
goblet
cell
hyperplasia
copd
lead
viscou
mucu
airway
imped
proper
ciliari
motion
mous
model
respiratori
virus
induc
mucu
hypersecret
contribut
inabl
clear
viru
airway
exacerb
infecti
caus
approxim
half
bacteri
origin
approxim
viral
numer
studi
perform
classifi
common
pathogen
implic
aecopd
use
sputum
sampl
identifi
bacteria
nasopharyng
swab
identifi
virus
landmark
studi
sethi
et
al
trace
longitudin
sputum
cultur
moderatetosever
copd
patient
time
clinic
stabil
exacerb
interestingli
acquisit
new
strain
bacteria
discov
molecular
type
highli
associ
develop
aecopd
rel
risk
exacerb
vari
new
speci
h
influenza
pneumonia
catarrhali
sinc
sensit
quantit
pcr
method
identifi
bacteria
rel
standard
cultur
method
enabl
better
quantif
type
bacteri
strain
exacerb
one
studi
speci
h
influenza
pneumonia
identifi
stabl
state
rel
load
determin
pcr
consider
higher
exacerb
cfuml
vs
cfuml
speci
preval
speci
identifi
exacerb
pneumonia
follow
h
influenza
catarrhali
legionella
pneumophila
sever
copd
patient
forc
expiratori
volum
fev
predict
pseudomona
aeruginosa
also
frequent
encount
caus
exacerb
tabl
pseudomona
aeruginosa
infect
appear
portend
wors
prognosi
higher
mortal
rate
compar
exacerb
associ
bacterium
virus
implic
develop
aecopd
includ
respiratori
syncyti
viru
rsv
rhinoviru
human
metapneumoviru
influenza
parainfluenza
adenoviru
coronaviru
metaanalysi
studi
total
patient
evalu
pool
preval
respiratori
virus
aecopd
found
rhinovirusesenterovirus
commonli
encount
viru
follow
rsv
influenza
lesser
preval
coronavirus
parainfluenza
human
metapneumoviru
adenoviru
coinfect
two
virus
also
report
one
studi
note
cohort
patient
viral
coinfect
sever
enough
admit
hospit
exacerb
simultan
bacteri
viral
pathogen
detect
acut
exacerb
remain
unclear
whether
coinfect
carri
greater
risk
poor
outcom
comparison
singl
infect
inde
may
simpli
repres
sever
diseas
studi
detect
compel
notion
superinfect
acut
viral
infect
copd
may
set
necessari
microenviron
lung
subsequ
bacteri
infect
vice
versa
experiment
rhinoviru
infect
copd
control
patient
nasal
inocul
low
dose
rhinoviru
copd
patient
develop
signific
increas
sputum
bacteri
load
postvir
infect
sputum
viral
load
peak
day
postinocul
bacteri
load
peak
later
around
day
confirm
studi
viral
infect
promot
bacteri
superinfect
subject
ultim
develop
secondari
bacteri
infect
lower
baselin
fev
compar
remain
free
secondari
infect
plausibl
mechan
suggest
wherebi
rhinoviru
infect
induc
neutrophil
elastas
ne
product
degrad
antimicrobi
peptid
elafin
secretori
leukoproteas
inhibitor
may
import
protect
subject
bacteri
infect
data
suggest
aecopd
event
thought
bacteri
induc
may
fact
preced
initi
viral
infect
moreov
greater
vigil
superinfect
patient
sever
lung
function
may
warrant
microorgan
commonli
detect
airway
stabl
copd
consid
colon
absenc
acut
infect
symptom
tabl
howev
term
colon
context
may
debat
microorgan
identifi
stabl
copd
necessarili
benign
collect
evid
favour
viciou
cycl
hypothesi
wherebi
incit
event
eg
smoke
lead
impair
innat
immun
respons
result
bacteri
colon
turn
promot
airway
system
inflamm
lead
copd
progress
airway
inflamm
persist
despit
smoke
cessat
presenc
persist
stimulusindepend
cigarett
smokei
consist
role
colon
bacteria
pathogenesi
copd
recognit
pathogenassoci
molecular
pattern
pamp
pattern
recognit
receptor
prr
express
epitheli
innat
immun
cell
activ
signal
transduct
pathway
includ
nuclear
factor
kappab
mitogenactiv
protein
kinas
ifn
regulatori
factor
result
product
proinflammatori
mediat
cytokin
chemokin
turn
recruit
neutrophil
airway
ensu
featur
characterist
bacteri
colon
copd
patient
neutrophil
antiinfect
recent
found
modulatori
function
copd
neutrophil
intrins
alter
abnorm
host
defenc
function
unusu
chemotact
behaviour
migratori
structur
activ
neutrophil
caus
lung
destruct
emphysemat
chang
releas
oxygen
radic
proteolyt
enzym
includ
ne
reduc
ciliari
function
induc
epitheli
damag
potent
stimul
mucin
product
result
mucu
product
impair
mucociliari
clearanc
lead
bacteri
colon
airway
obstruct
addit
increas
level
airway
inflammatori
marker
leukotrien
matrix
metalloproteinas
mmp
myeloperoxidas
mpo
ne
found
stabl
copd
patient
bacteri
colon
compar
without
bacteri
colon
strongli
implic
colon
state
deleteri
immun
respons
persist
inflamm
associ
increas
daili
symptom
exacerb
mortal
defect
phagocytosi
also
characterist
copd
particularli
alveolarand
monocytederiv
macrophag
turn
like
contribut
chronic
bacteri
colon
infect
exacerb
clearli
evidenc
observ
impair
phagocytosi
h
influenza
catarrhali
increas
copd
sever
addit
alveolar
macrophag
surfac
receptor
scaveng
receptor
marco
respond
intracellular
signal
phagocytosi
seen
diminish
copd
smoker
chronic
bacteri
colon
also
activ
adapt
immun
respons
develop
bcell
lymphoid
follicl
product
mucos
iga
serum
igg
antibodi
includ
strainspecif
igg
antibodi
bacteri
colon
phenomenon
characterist
copd
airway
increas
lymphoid
follicl
note
small
airway
patient
sever
copd
possibl
secondari
chronic
airway
infect
thu
impair
innat
immun
respons
like
contribut
microbi
airway
colon
activ
adapt
immun
suggest
state
heighten
immun
surveil
associ
lung
function
declin
establish
copd
potenti
pathogen
microorgan
ppm
isol
stabl
copd
patient
commonest
ppm
identifi
includ
h
influenza
catarrhali
pneumonia
p
aeruginosa
chlamydophila
pneumonia
similar
culprit
repertoir
aecopd
sever
asthma
bacteri
colon
howev
dynam
process
alter
pathogen
type
load
strain
time
increas
bacteri
load
chang
speci
associ
greater
lung
function
declin
airway
inflamm
nontyp
h
influenza
nthi
common
bacteria
isol
stabl
state
aecopd
alon
account
half
bacteria
isol
lower
airway
stabl
copd
patient
differ
cell
surfac
protein
facilit
bacteri
adhes
respiratori
mucosa
includ
outer
membran
protein
bind
mucin
adhesin
adher
epitheli
extracellular
matrix
lipooligosaccharid
key
compon
nthi
cell
wall
outer
membran
protein
potent
immunomodul
macrophag
lead
increas
phagocytosi
cytokin
secret
includ
drive
neutrophil
recruit
given
defect
phagocyt
abil
copd
alveolar
macrophag
failur
bacteri
clearanc
potenti
lead
state
persist
infect
furthermor
nthi
uniqu
abl
surviv
intracellularli
within
alveolar
macrophag
secret
proteas
cleav
iga
turn
protect
igamedi
cytotox
persist
copd
nthi
infect
lower
airway
result
increas
inflamm
elev
level
mpo
detect
patient
sampl
critic
organ
immunoevas
abil
caus
chronic
airway
inflamm
turn
correl
poorer
health
statu
lung
function
moraxella
catarrhali
second
preval
colon
organ
stabl
copd
seen
shown
previou
studi
link
heighten
airway
inflamm
ne
contrast
nthi
bacterium
clear
rel
short
colon
period
develop
immun
respons
protect
homolog
strain
streptococcu
pneumonia
anoth
import
bacteri
organ
stabl
copd
polysaccharid
capsul
reduc
effect
host
defenc
mechan
normal
caus
clearanc
lead
airway
persist
colon
turn
associ
increas
exacerb
emphysema
lower
diffus
capac
pneumonia
role
p
aeruginosa
copd
pathogenesi
underscor
frequent
isol
patient
sever
diseas
two
type
pseudomonasrel
infect
describ
copd
set
shortterm
colon
follow
clearanc
longterm
persist
colon
risk
factor
pseudomona
isol
copd
includ
bronchiectasi
antibiot
exposur
previou
hospit
steroid
use
wors
bode
index
mucoid
phenotyp
like
caus
persist
colon
amongst
p
aeruginosaposit
copd
patient
signific
associ
colon
diseas
sever
despit
nest
casecontrol
studi
compar
mortal
show
differ
relat
pseudomona
statu
stabl
copd
howev
aecopd
recent
work
reaffirm
organ
associ
higher
copd
mortal
rate
final
chronic
c
pneumonia
infect
copd
brought
light
number
observ
studi
induct
cytokin
respons
airway
inflamm
critic
airway
remodel
ensu
preval
vari
wide
like
attribut
lack
sampl
collect
standard
appli
microbiolog
methodolog
lack
diagnost
test
routin
use
despit
serum
c
pneumoniaespecif
igg
iga
antibodi
level
found
higher
titr
copd
compar
control
group
furthermor
statist
signific
associ
chronic
c
pneumonia
infect
copd
establish
employ
combin
pcr
serolog
test
reveal
chronic
c
pneumonia
infect
associ
sever
copd
faster
lung
function
declin
importantli
exacerb
relationship
howev
clear
cut
separ
studi
copd
patient
show
associ
chlamydia
either
copd
exacerb
frequenc
fev
latter
studi
igg
titr
use
defin
chronic
c
pneumonia
infect
may
explain
observ
dispar
furthermor
like
chlamydia
resid
lower
respiratori
tract
sampl
need
occur
site
standard
valid
reproduc
robust
diagnost
test
clearli
defin
c
pneumonia
infect
copd
necessari
like
clarifi
exist
differ
observ
current
evid
base
mycobacteri
diseas
nontubercul
mycobacteria
ntm
tuberculosi
tb
long
associ
copd
whether
thought
relat
inabl
clear
chronic
pathogen
set
structur
damag
lung
potenti
concurr
burden
bronchiectasi
increasingli
appreci
copd
studi
ntm
copd
cohort
reveal
roughli
onefifth
copd
patient
cultur
ntm
sputum
moreov
copd
patient
undergo
lung
volum
reduct
surgeri
histolog
evid
mycobacteri
diseas
necrot
granuloma
occur
patient
acidfast
bacilli
afb
posit
stain
convers
copd
appear
major
comorbid
patient
ntm
estim
preval
rang
mere
innoc
bystand
ntm
infect
copd
portend
wors
prognosi
frequent
exacerb
rapid
declin
fev
howev
longterm
prospect
studi
impact
ntm
copd
mortal
antimycobacteri
treatment
outcom
copd
yet
perform
relationship
tb
copd
date
back
anno
tomashefski
first
describ
airflow
obstruct
air
trap
patient
tb
sinc
link
tb
copd
larg
focus
copd
sequela
tb
infect
risk
consist
appear
independ
smoke
histori
proport
copd
patient
found
harbour
histori
tb
list
tabl
worldwid
estim
preval
airflow
obstruct
cohort
tb
patient
list
tabl
patient
histori
tb
carri
anywher
worldwid
estim
south
africa
time
overal
risk
develop
copd
particular
tb
remain
import
risk
factor
copd
nonsmok
tb
patient
carri
estim
time
risk
develop
copd
compar
without
tb
likewis
copd
patient
higher
risk
develop
tb
pakistan
instanc
copd
patient
found
tbposit
sputum
cultur
even
nonendem
region
exampl
sweden
copd
patient
carri
three
time
higher
likelihood
develop
activ
tb
confer
twofold
higher
risk
death
compar
copd
patient
without
tb
tb
may
predispos
individu
copd
vice
versa
matter
specul
outlin
figur
condit
share
number
common
risk
factor
includ
cigarett
smoke
biomass
fuel
exposur
addit
spread
hiv
clinic
signific
fungal
infect
copd
poorli
understood
like
underestim
fungal
colon
observ
sever
copd
patient
whether
colon
marker
advanc
copd
contribut
diseas
progress
remain
studi
aspergillu
spp
frequent
isol
airway
copd
patient
exacerb
even
followup
observ
studi
posit
aspergillu
cultur
copd
patient
associ
increas
sputum
cell
count
incid
aecopd
preced
year
concomit
bacteri
pathogen
isol
associ
increas
aspergillu
detect
posit
aspergillu
cultur
copd
patient
associ
increas
sputum
neutrophil
suggest
presenc
host
immun
respons
relat
organ
copd
patient
hypersensit
aspergillu
associ
reduc
lung
function
whether
use
antifung
may
mitig
declin
pulmonari
function
remain
studi
isol
aspergillu
airway
may
repres
temporari
passag
benign
carriag
earli
sign
invas
pulmonari
aspergillosi
ipa
especi
high
steroid
use
recurr
exacerb
confer
host
immunosuppress
increas
evid
suggest
copd
patient
risk
ipa
result
high
mortal
rate
copd
patient
detect
aspergillu
airway
cultur
ipa
innat
immun
respons
play
import
role
aspergillu
clearanc
mechan
inhal
aspergillu
conidia
bind
surfac
receptor
within
termin
airway
via
galactomannan
enhanc
uptak
alveolar
macrophag
dendrit
cell
lead
cascad
immun
respons
recruit
neutrophil
alveolar
macrophag
lead
ingest
phagolysosom
degrad
kill
fungal
conidia
signal
contribut
host
recognit
inflammatori
respons
aspergillu
conidia
hypha
steroid
therefor
interfer
alveolar
macrophag
function
therebi
increas
risk
ipa
defect
innat
immun
respons
copd
includ
function
abnorm
neutrophil
tlr
pneumocysti
jirovecii
anoth
opportunist
fungal
pathogen
copd
lung
patient
pneumocysti
colon
describ
sever
copd
patient
gold
stage
iv
compar
milder
diseas
gold
stage
colon
associ
sever
airflow
obstruct
independ
smoke
increas
system
inflamm
proteas
respons
parenchym
destruct
emphysema
copd
found
higher
concentr
copd
patient
colon
pneumocysti
suggest
organ
unlik
innoc
bystand
may
contribut
diseas
pathogenesi
progress
upregul
chemokin
ligand
receptor
predominantli
express
activ
thelper
th
lymphocyt
also
observ
may
prime
inflammatori
pathway
contribut
progress
copd
case
although
respiratori
virus
associ
asthma
copd
caus
acut
cell
damag
releas
ro
activ
signific
stabl
copd
less
well
understood
tabl
adenoviru
dna
detect
lung
tissu
stabl
copd
patient
compar
healthi
smoker
increas
adenoviru
earli
region
express
observ
patient
emphysema
anim
model
even
latent
adenoviru
infect
amplifi
inflammatori
respons
increas
cluster
differenti
cd
cell
macrophag
neutrophil
emphysemat
destruct
increas
intercellular
adhes
molecul
express
also
describ
human
epitheli
cell
transfect
adenoviru
gene
rsv
also
common
stabl
copd
preval
rate
rna
viru
pararmyxovirida
famili
common
caus
acut
respiratori
tract
infect
presenc
stabl
copd
unsurprisingli
link
higher
level
airway
system
inflamm
emerg
role
microbiom
stabl
exacerb
copd
recent
review
elsewher
research
focus
bacteriom
virus
virom
fungi
mycobiom
also
import
constitu
microbiom
respiratori
tract
contain
genet
materi
eukaryot
virus
anellovirus
herpesvirus
papillomavirus
well
retrovirus
may
establish
persist
asymptomat
infect
bacteriophag
domin
virom
lung
virom
highli
variabl
individu
strongli
influenc
environment
condit
oxygen
avail
unfortun
mani
studi
larg
proport
sequenc
read
match
refer
genom
unclear
whether
identifi
virus
commens
latent
infect
given
difficulti
challeng
directli
compar
entir
virom
copd
patient
healthi
subject
nevertheless
copd
patient
increas
total
viral
load
well
increas
preval
abund
influenza
cytomegaloviru
epsteinbarr
viru
ultim
role
acut
viral
infect
includ
rhinoviru
rsv
influenza
clearli
contribut
inflamm
patholog
exacerb
copd
remain
fulli
elucid
previous
describ
latent
adenovir
infect
associ
increas
inflamm
alveolar
destruct
total
influenzaspecif
viral
load
copd
patient
without
symptom
infect
correl
inflammatori
cell
number
airway
moreov
human
rhinovirusencod
proteinas
propos
elicit
duel
respons
copd
patient
impact
dendrit
cell
matur
therebi
drive
inflamm
allergi
airway
obstruct
although
fungi
detect
low
abund
healthi
individu
sever
member
mycobiom
consist
identifi
lower
respiratori
tract
includ
cladosporium
aspergillu
spp
moreov
outgrowth
aspergillu
lead
ipa
copd
common
predispos
condit
colon
pneumocysti
associ
copd
develop
gold
stage
classif
pneumocysti
spp
capabl
induc
copdlik
diseas
anim
model
without
cigarett
smoke
exposur
oral
caviti
smoke
associ
increas
preval
candida
spp
consequ
abil
cigarett
smoke
increas
growth
adher
immunostimulatori
activ
candida
albican
cigarett
smoke
also
increas
content
chitin
cell
wall
c
albican
clear
whether
cigarett
smoke
caus
similar
chang
fungi
colon
lung
fungi
oral
caviti
affect
lung
microaspir
notabl
activ
chitotriosidas
chitinbind
protein
increas
bal
alveolar
macrophag
copd
patient
even
serum
level
chitotriosidas
elev
copd
patient
invers
correl
lung
function
indic
host
respons
fungal
colon
may
contribut
copd
progress
bacteri
microbiom
virom
mycobiom
isol
act
concert
inde
bacteria
phage
popul
strongli
correl
eukaryot
virus
fungi
affect
bacteri
growth
furthermor
gastrointestin
microbiom
interact
respiratori
microbiota
play
critic
role
develop
sever
chronic
respiratori
diseas
like
copd
fig
promin
role
bacteria
incit
acut
copd
exacerb
place
antibiot
forefront
copd
therapi
anthonisen
et
al
report
increas
treatment
success
rate
antibiot
therapi
compar
placebo
particularli
patient
increas
dyspnoea
sputum
product
purul
sinc
antibiot
cover
pathogen
h
influenza
pneumonia
catarrhali
becom
mainstay
therapi
numer
trial
confirm
benefici
effect
nonetheless
notion
acut
exacerb
must
treat
antibiot
call
question
given
everi
exacerb
result
bacteri
infect
effort
better
identifi
subset
exacerb
copd
patient
may
benefit
antibiot
explor
biomark
procalcitonin
creactiv
protein
neutrophil
express
yet
made
mainstream
clinic
decis
algorithm
pleiotrop
effect
antibiot
particularli
macrolid
class
also
antiinflammatori
properti
led
use
prevent
exacerb
azithromycin
instanc
antimicrobi
activ
gramposit
neg
pathogen
also
antiinflammatori
immunomodulatori
effect
treatment
stabl
copd
patient
reduc
sever
exacerb
popul
patient
frequent
copd
exacerb
chronic
use
azithromycin
result
significantli
longer
time
first
exacerb
reduc
yearli
exacerb
rate
azithromycin
particularli
effect
reduc
exacerb
requir
antibiot
system
corticosteroid
appear
effect
older
patient
milder
diseas
longterm
effect
chronic
azithromycin
therapi
lung
microbi
commun
howev
yet
determin
although
initi
report
suggest
overal
bacteri
burden
remain
stabl
alpha
divers
lung
decreas
significantli
implic
chang
yet
establish
therapi
proven
benefici
copd
patient
import
rememb
copd
treatment
untoward
microbi
effect
icss
instanc
shown
increas
risk
figur
role
microbiom
copd
pathogenesi
progress
bacteria
virus
fungi
enter
lung
breath
microaspir
oral
microb
healthi
lung
homeostasi
achiev
appropri
immun
respons
pathogen
clearanc
copd
increas
abund
pathogen
organ
oral
taxa
seen
associ
reduc
overal
bacteri
divers
consequ
perpetu
deleteri
immun
respons
occur
associ
copd
progress
hostmicrob
dialogu
may
also
proceed
via
gutlung
axi
exacerb
diseas
symptom
demonstr
chronic
respiratori
diseas
state
ipa
invas
pulmonari
aspergillosi
th
thelper
pneumonia
tb
initi
random
control
trial
studi
ic
icslongact
laba
combin
drug
higher
rate
pneumonia
note
icscontain
treatment
group
subsequ
analys
howev
specif
implic
fluticason
ic
like
increas
risk
pneumonia
budesonid
appear
confer
signific
risk
similarli
risk
develop
tb
ic
therapi
signific
moder
highli
tb
endem
area
research
taiwan
south
korea
demonstr
time
greater
risk
develop
tb
ic
treatment
dosedepend
effect
thu
endem
area
clinician
vigil
develop
tb
copd
patient
ic
therapi
addit
geograph
distinct
infect
uniform
copd
chang
pathogen
strain
load
time
differ
speci
trigger
distinct
inflammatori
respons
furthermor
host
factor
play
essenti
role
infect
manifest
outcom
result
variabl
respons
antibiot
treatment
copd
therapi
longterm
macrolid
benefici
reduct
exacerb
rate
select
group
patient
copd
effect
link
antiinflammatori
properti
macrolid
like
explain
impact
microbiom
turn
modul
immun
tone
cultureindepend
molecular
techniqu
construct
comprehens
analysi
microbi
commun
lower
airway
yet
complex
interact
host
pathogen
environ
contribut
diseas
manifest
progress
copd
far
understood
futur
studi
requir
better
defin
contribut
infect
copd
pathogenesi
intervent
studi
incorpor
antimicrobi
antiinflammatori
approach
treatment
copd
applic
wholegenom
metagenom
context
may
uncov
mechan
beyond
scope
culturebas
amplicon
sequenc
approach
reveal
precis
genet
metabol
pathway
intersect
key
immun
respons
contribut
diseas
progress
differ
risk
factor
exposur
ethnogeographi
genet
background
asia
result
distinct
characterist
asian
copd
current
overlook
exist
copd
treatment
guidelin
mani
copd
risk
factor
includ
indoor
outdoor
air
pollut
occup
exposur
dust
fume
histori
repeat
childhood
respiratori
tract
infect
intrauterin
growth
retard
pulmonari
tb
poor
socioeconom
statu
observ
higher
preval
asiapacif
region
particular
note
higher
preval
pulmonari
tb
among
asian
copd
patient
concomit
ntm
tb
bronchiectasi
copd
associ
higher
risk
exacerb
greater
declin
pulmonari
function
increas
risk
mortal
furthermor
asia
epicentr
antimicrobi
resist
high
preval
multidrug
resist
mdr
organ
includ
respiratori
pathogen
consequ
may
differ
respons
antibiot
therapi
bacteri
exacerb
copd
array
variabl
organ
identifi
aecopd
asiapacif
region
gramneg
bacteria
includ
p
aeruginosa
klebsiella
pneumonia
acinetobact
spp
common
aecopd
asiapacif
region
distinct
risk
factor
exposur
compar
western
cohort
underutil
spirometri
higher
preval
tb
bronchiectasi
antibiot
resist
pose
uniqu
challeng
better
diagnosi
treatment
copd
particular
asiapacif
region
excess
mucu
product
copd
patient
fertil
ground
stimul
chronic
bacteri
infect
puls
therapi
antibiot
frequent
use
control
bacteri
multipl
consequ
promot
develop
antimicrobi
resist
prolong
use
macrolid
prophylaxi
treatment
copd
exacerb
shown
increas
antimicrobi
drug
resist
h
influenza
commonli
use
drug
azithromycin
long
halflif
around
h
lead
drug
concentr
minimum
inhibitori
concentr
extend
period
time
prolong
exposur
subinhibitori
concentr
drug
may
one
reason
behind
increas
resist
macrolid
inde
studi
desai
et
al
copd
patient
pneumonia
infect
show
correl
exposur
macrolid
develop
resist
advis
use
altern
antibiot
patient
take
macrolid
previou
month
longitudin
studi
conduct
pettigrew
et
al
conclud
fluoroquinolon
repres
best
choic
erad
h
influenza
copd
patient
studi
none
bacteri
isol
develop
resist
fluoroquinolon
even
though
p
aeruginosa
rel
uncommon
caus
copd
exacerb
incid
rise
rapid
emerg
spread
mdr
defin
resist
least
three
antibiot
class
seriou
caus
concern
compar
studi
conduct
spain
demonstr
carriag
mdr
p
aeruginosa
copd
patient
associ
increas
mortal
rate
recent
work
aecopd
reveal
high
burden
antibiot
resist
lung
environ
found
copd
patient
also
favour
format
biofilm
mechan
bacteria
particularli
p
aeruginosa
h
influenza
evad
antibiot
kill
addit
limit
antimicrobi
penetr
biofilm
trigger
emerg
rel
quiescent
bacteria
becom
phenotyp
drug
resist
antibiot
therefor
increas
persist
prolong
period
time
current
effect
way
curb
antimicrobi
resist
reduc
use
antibiot
prescrib
patient
demonstr
patholog
bacteri
infect
respect
use
sensit
marker
bacteri
infect
procalcitonin
guid
start
antibiot
therapi
shown
significantli
reduc
use
antibiot
copd
patient
also
potenti
new
therapi
develop
steroidresist
asthma
may
also
benefici
copd
possibl
avoid
infectioninduc
effect
ic
major
studi
describ
associ
infect
microbiom
copd
human
studi
limit
type
sampl
collect
typic
crosssect
natur
studi
design
mous
model
cigarett
smokeinduc
experiment
copd
accur
recapitul
hallmark
featur
human
diseas
gener
chronic
model
use
inhal
exposur
drive
develop
airway
inflamm
remodel
mucu
hypersecret
emphysema
chang
lung
function
similar
human
achiev
rel
short
time
frame
week
exposur
similar
packaday
human
smoker
importantli
model
increas
suscept
respiratori
bacteri
viral
infect
relev
human
describ
use
assess
mechan
associ
infect
microbiom
copd
recent
implic
role
immun
defect
microrna
mast
cell
proteas
mani
factor
combin
parallel
ex
vivo
human
sampl
primari
cell
cultur
analysi
provid
power
tool
explor
associ
valuabl
test
new
drug
translat
human
address
appli
treatment
specif
patient
alter
drug
target
similar
analysi
compar
tissu
mice
human
use
similar
techniqu
interrog
precisioncut
lung
slice
import
therapeut
question
examin
futur
copd
studi
although
role
pathogen
microb
aecopd
extens
investig
clinic
signific
stabl
colon
copd
patient
remain
less
clear
question
whether
colon
microb
activ
contribut
copd
pathogenesi
importantli
progress
may
difficult
address
current
evid
base
given
technic
challeng
detect
organ
subtleti
associ
diseas
long
period
time
nevertheless
immun
respons
observ
stabl
colon
copd
patient
reflect
corollari
seen
aecopd
support
role
microbi
colon
copd
pathogenesi
like
perpetu
neg
immun
respons
time
initi
work
start
uncov
chang
lung
microbiom
associ
copd
state
may
reveal
variabl
consid
investig
microbecopd
interact
parallel
use
mous
model
interrog
human
sampl
ex
vivo
primari
cell
cultur
like
progress
mechanist
insight
drug
develop
importantli
howev
variabl
microbiom
composit
may
confound
pathogencentr
investig
diseasemicrob
interact
like
largescal
studi
requir
address
current
gap
knowledg
bacteri
viral
fungal
microbiota
associ
copd
precipit
drop
cost
dna
sequenc
coupl
technolog
innov
metagenom
may
soon
bring
technolog
realm
routin
diagnost
copd
could
allow
refin
patient
phenotyp
stratif
turn
allow
focus
person
therapi
base
microbiolog
final
impact
antimicrobi
therapi
use
antibiot
prophylaxi
respiratori
microbiom
provid
challeng
extens
remodel
microbiom
occur
respons
copd
antibiot
treatment
recogn
unclear
longterm
consequ
patient
